| Revenue growth | 23.7% YoY in Q1FY27; 32% CAGR (FY23-26). |
|---|---|
| Margins | Adjusted EBITDA margin expanded 120 bps YoY to 23.1%. |
| Demand visibility | High; driven by diabetes, hypertension, and dialysis under-penetration. |
| Management confidence | Strong; citing India platform strength and operating leverage. |
Growth
Adjusted EBITDA grew 30.7% YoY to ₹65.1 Cr; Adjusted PAT rose 41.7% YoY to ₹36.8 Cr.
Outlook
Targeting high growth in India Tier 2/3 cities and international expansion in Philippines, Uzbekistan, and KSA.
Risks
High reliance on renal nurse availability; international market entry risks via JVs/acquisitions; competitive bidding for PPP tenders.
Last quarter's promises, checked
Delivered
- Guided 15-20% revenue CAGR → delivered 23.7% YoY (= BEAT)
- Guided 40-50 India clinic additions → delivered 12-15% guest growth (= BEAT)
- Guided international expansion focus → delivered 45% revenue mix (= BEAT)
Partly delivered
- Guided 10-15 Philippines roll-ups → delivered 7 acquisitions in Q1 (= PARTIAL)
Investor Presentation filed with NSE, NSE: NEPHROPLUS. Summary written with AI assistance from the document.
Nephrocare Health Services Ltd: key numbers
- Share price
- ₹643.00
- Market cap
- ₹6,452 Cr
- Revenue (annual)
- ₹998.8 Cr
- Net profit (annual)
- ₹76.84 Cr
- P/E (TTM)
- 75.8×Sector 53.1×
- Promoter holding
- 63.85%+0.00% QoQ
- FII holding
- 8.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nephrocare Health Services Ltd
All →Nephrocare Health Services Credit Rating
India Ratings upgraded Nephrocare Health Services' long-term bank loan facilities to IND AA-/Stable. The agency also affirmed the company's short-term credit ratings.
Nephrocare Health Services Merger & Restructuring
Nephrocare Health Services Ltd announced the rationalisation and consolidation of its step-down subsidiaries in the Philippines. This internal reorganization streamlines the group's existing structure.
Nephrocare Health Services Merger & Restructuring Worth ₹10.25 Cr
Nephrocare's Philippines subsidiary acquired a dialysis center from Renal One Dialysis Corp for ≈₹10.25 Cr. The asset transfer expands the company's dialysis network.
- Value
- ₹10.25 Cr
- dialysis center acquired
- 1 dialysis centers
Nephrocare Health Services Acquisition Worth ₹10.25 Cr
Nephrocare's Philippines subsidiary is acquiring a dialysis center from Renal One Dialysis Corp. for a consideration of ₹10.25 crore.
- Value
- ₹10.25 Cr
Nephrocare Health Services Employee Stock Options
Nephrocare Health Services granted 4,01,362 employee stock options at an exercise price of ₹230 per share. These options are issued under the NephroPlus Employee Stock Option Scheme 2026.
Nephrocare Health Services Acquisition Worth ₹11.63 Cr
Nephroplus Health Services Kazakhstan LLP will acquire a 100% stake in 'Dialysis Center Almaty' LLP for approximately ₹11.64 Crore to expand its international dialysis network.
- Value
- ₹11.63 Cr